First Stab at Combination Therapy Yields Additive Effect
The last day of the meeting unfolded as is often the case at long conferences: Some of the most anticipated talks spilled their new data before sparse audiences...
302 RESULTS
Sort By:
The last day of the meeting unfolded as is often the case at long conferences: Some of the most anticipated talks spilled their new data before sparse audiences...
Like a knot in your shoelace, entwined mRNAs can interfere with the nucleic acid’s normal actions...
Why are women at greater risk for Alzheimer's disease?...
Are fewer people getting Alzheimer’s disease now than they did 20 years ago?...
Scientists continue to squeeze every last bit of information out of Phase 3 trials for anti-amyloid antibodies solanezumab and bapineuzumab...
Satori Pharmaceuticals, which had been developing γ-secretase modulators for the treatment of Alzheimer's disease, has closed its doors...
Researchers performed a genomewide association study (GWAS) to find markers associated with elevated levels of tau and phosphorylated tau in cerebrospinal fluid (CSF)...
In the first GWAS based on amyloid imaging, researchers have uncovered single nucleotide polymorphisms near the genes encoding butyrylcholinesterase (BChE) and ApoE...
Could cranking up a cellular waste removal system help rid the brain of misfolded α-synuclein, the principle component of Lewy bodies found in neurodegenerative disorders such as Parkinson’s disease?
An oligonucleotide designed to tamp down an enzyme that causes amyotrophic lateral sclerosis seems safe...
Leaders protest recent decision to deny Medicare beneficiaries coverage of amyloid scans.
The proportion of seniors with dementia in England appears to be on the decline, new research suggests.
Researchers at AAIC 2013 report that an individual’s subjective sense of worsening memory could be an important predictor of cognitive impairment and dementia.
Update on compounds in Phase 2 and 3 trials from the Alzheimer's Association International Conference
Speakers at Alzheimer’s conference reviewed planned Phase 1 and prevention trials and preclinical studies.